Clinical Trial Update: Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents [Phase 2]

View source ↗

Summary

A Phase 2 trial update evaluating low-dose deferasirox in adults with low-risk myelodysplastic syndromes who are resistant or relapsing after erythropoiesis-sti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Deferasirox (Deferasirox)

Snippet

Sponsor: University Hospital, Grenoble | Conditions: Myelodysplasia | Phase 2 | Status: COMPLETED